Denali Therapeutics (DNLI) Operating Margin (2018 - 2023)
Denali Therapeutics (DNLI) reported Operating Margin of 8981.45% for Q3 2023, up 4943485.0% year-over-year from N/an in Q3 2022, and down 15595.1% on a QoQ basis from 57.96% in Q2 2023.
Denali Therapeutics (DNLI) has 6 years of Operating Margin data on file, last reported at 8981.45% in Q3 2023.
- Quarterly Operating Margin rose 4943485.0% year-over-year to 8981.45% in Q3 2023, while the trailing twelve-month figure through Jun 2024 was 37938.04% (down 3788998.0% YoY) and the FY2023 annual result came in at 59.51%, up 996827.0% from the prior year.
- Operating Margin eased to 8981.45% in Q3 2023 per DNLI's latest filing, from 57.96% in the prior quarter.
- Across five years, Operating Margin topped out at 77.04% in Q4 2020 and bottomed at 7122000.0% in Q1 2021.
- The 5-year median for Operating Margin is 1053.44% (2022), against an average of 454218.99%.
- The widest annual swing landed in 2021, when Operating Margin slumped 700667885 bps; it then soared 712184220 bps in 2022.
- Tracing DNLI's Operating Margin over 5 years: stood at 1236.26% in 2019, then surged by 106 bps to 77.04% in 2020, then tumbled by 900 bps to 616.28% in 2021, then plunged by 71 bps to 1053.44% in 2022, then plunged by 753 bps to 8981.45% in 2023.
- Per Business Quant, the three latest DNLI Operating Margin figures stand at 8981.45% (Q3 2023), 57.96% (Q2 2023), and 343.8% (Q1 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Denali Therapeutics | 3.82 Bn | 3.82 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -8,981.45% |
| Jun 30, 2023 | 57.96% |
| Mar 31, 2023 | -343.80% |
| Dec 31, 2022 | -1,053.44% |
| Sep 30, 2022 | -58,416.30% |
| Jun 30, 2022 | -117.03% |
| Mar 31, 2022 | -157.80% |
| Dec 31, 2021 | -616.28% |
| Sep 30, 2021 | -1,619.55% |
| Jun 30, 2021 | -412.11% |
| Mar 31, 2021 | -7,122,000.00% |
| Dec 31, 2020 | 77.04% |
| Sep 30, 2020 | -1,202,320.00% |
| Jun 30, 2020 | -1,048.01% |
| Mar 31, 2020 | -115,321.15% |
| Dec 31, 2019 | -1,236.26% |
| Sep 30, 2019 | -52,244.79% |
| Jun 30, 2019 | -63,396.97% |
| Mar 31, 2019 | -1,010.89% |
| Dec 31, 2018 | 59.48% |
| Sep 30, 2018 | -3,176.90% |
| Jun 30, 2018 | -3,481.92% |
| Mar 31, 2018 | -4,016.85% |